NKGen Biotech, Inc.

Graf Acquisition Corp. IV (Nasdaq: GFOR) was a blank-check company sponsored by Graf Acquisition LLC, the vehicle of serial SPAC sponsor James Graf, which completed its initial public offering in 2022 targeting the healthcare and biotechnology sector. On September 29, 2023, GFOR announced a definitive business combination agreement with NKGen Biotech, Inc., a clinical-stage biopharmaceutical company developing allogeneic natural killer cell therapies for oncology and neurological indications. The transaction has since closed, with NKGen Biotech emerging as the surviving public entity following the de-SPAC process. Investors tracking closed SPAC-to-biotech transactions can access full filings, deal timelines, and pipeline analytics by signing up for complete data on SpacDesk.

SPAC Counterparty (1)